• Latest field trials validate strength of Biotalys’ first biocontrol Evoca

    Thursday May 19th 2022

  • KU Leuven announces collaboration and license agreement with Gilead Sciences for the development of new antivirals against the respiratory syncytial virus

    Wednesday May 18th 2022

  • QbD Group requalifies as Best Managed Company

    Friday May 13th 2022

  • Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions

    Thursday May 12th 2022

  • Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

    Thursday May 12th 2022

  • Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications

    Tuesday May 10th 2022

  • UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Tuesday May 10th 2022

  • Quality by Design (QbD) becomes QbD Group, consolidating its offerings to support the development of innovative life science products, “from idea to patient”

    Monday May 9th 2022

  • Your news here?

  • Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)

    Monday May 9th 2022

  • Ziphius Vaccines and Ghent University publish promising data from self-amplifying RNA platform in Molecular Therapy

    Friday May 6th 2022

  • argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia

    Thursday May 5th 2022

Strategic Partners